Medpace raised its 2026 earnings-per-share (EPS) guidance range, according to an October 21 headline. The supplied information does not include the old or new range, the size of the increase, or the company’s reason for raising it. Other headlines mention Q3 results and revenue guidance, but provide no supporting figures.
Investor takeaway: Medpace raised its 2026 EPS guidance, but the size and rationale for the change are not available in the supplied facts.
The revised 2026 EPS range was not provided
Advertisement
Medpace Holdings Inc
MEDP.US
MEDP.US
Medpace Holdings Inc
WealthAwesomeMarket cap
$17.37B
P/E
36.5x
52W high
$677.90
52W low
$373.00
1W change
+7.44%
Beta
1.18
Analyst Price Targets
Based on 14 analysts covering MEDP · as of Oct 12, 2026
Wall Street analysts forecast MEDP stock price to fall 10.0% over the next 12 months.
Consensus
Hold3.07 / 5.00
Avg. Target
C$595.92
-10.0% Upside
Previously C$594.54 on Oct 9, 2026
Current Price
C$662.48
Last close
Analyst Breakdown (14 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MEDP's historical volatility
30-Day Vol
32.0%
Annualized
90-Day Vol
38.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$792.00
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$703.11 | C$629.54 – C$785.28 |
| 60 trading days | C$746.23 | C$638.25 – C$872.48 |
| 90 trading days | C$792.00 | C$654.01 – C$959.10 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
The headline confirms an increase, but without the previous and revised ranges, investors can’t assess its size.
Bull case
Medpace raised its 2026 EPS guidance, improving its stated earnings outlook.
Bear case
The revised range and the assumptions behind it are unknown. Another headline says revenue guidance was below expectations, but provides no figures.
What happened: Medpace raised its 2026 EPS range
Medpace raised its 2026 earnings-per-share range, according to an October 21 headline. The supplied information does not give the previous or revised range, the size of the increase, or the reason for the change. It also includes no company statement or detailed financial release to clarify those points. Other October 21 headlines mention Q3 estimates and revenue guidance, but provide no figures that explain the EPS revision.
Advertisement
What the numbers show: no figures for the guidance change
The key figure—the revised 2026 EPS range—is missing. Medpace’s last close was US$662.48, up 6.43% for the day. Latest volume was 3,054 shares, compared with a 20-day average of 263,029. These figures provide market context, but the supplied information does not show that the price move or trading volume resulted from the guidance announcement. Medpace’s reported trailing P/E is 36.549 and its EPS (TTM) is 17.03, but neither figure tells us the new full-year guidance. See the [Medpace stock page (MEDP.US)](/stocks/medp-us).
What to watch next: the revised range and its assumptions
Look for the new and previous EPS guidance ranges, the assumptions behind the revision, and an explanation of how it relates to the company’s revenue outlook. A separate headline says Medpace’s revenue guidance was below expectations, but provides no forecast or comparison. The connection between that report and the higher EPS range is unclear. Without the figures and rationale, investors can’t assess the size or implications of the change. See the MEDP.US stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
